Introduction The prevalence of postpartum depression in China has been steadily increasing, and community-based interventions are considered an important measure to address this issue. This study aims ...

CT-155, an investigational prescription digital therapeutic, is safe and effective in reducing negative schizophrenia ...

Relay Therapeutics beat analyst estimates for both GAAP revenue and earnings per share in Q2 2025. The company reported continued clinical advancement of its lead asset RLY-2608, with new positive ...

Upadacitinib demonstrated significant efficacy in promoting scalp hair regrowth in severe alopecia areata patients, achieving primary endpoints in nearly half of the participants. The phase 3 trials ...

Key Points Collaboration revenue (GAAP) missed expectations by 43.8%. Collaboration revenue (GAAP) totaled $7.6 million against an estimate of $13.52 million. Significant clinical progress for lead ...

The randomized, double-blind, CONVOKE trial evaluated the safety and efficacy of CT-155, a PDT that provides interactive psychosocial intervention techniques via a smartphone app.

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Amylyx Pharmaceuticals, Inc. (($AMLX)) announced an update on their ongoing clinical study. Amylyx Pharmaceuticals, Inc. is conducting a Phase 1 ...

Intervention/Treatment: The trial tests Itepekimab, administered subcutaneously in high and low doses, alongside Mometasone furoate nasal spray. The purpose is to improve symptoms in patients with ...

Cardiol Therapeutics (TSX: CRDL) (NYSE: CRDL) has released topline results from their phase two ARCHER trial targeting ...

Operator: Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company ...